Eurofins Discovery

A new issue of Discovery Pulse is out! As obesity drug discovery moves beyond single-target therapies, understanding receptor selectivity, signaling pathways, and β-cell function is becoming increasingly important. In this issue, Lakshmi Anantharaman explores how Class B GPCR profiling, orthogonal assays, and GSIS studies can help support more informed lead optimization and candidate selection decisions. Read the newsletter and discover strategies for strengthening translational pharmacology in obesity programs. Don't miss the next issue, subscribe here: https://lnkd.in/eqWg2aD6 #Eurofins #EurofinsDiscovery #ObesityResearch #GPCR #TranslationalPharmacology #MetabolicDisorders

This new issue of Discovery Pulse highlights the growing impact of biophysics on kinase drug discovery. In this edition, Vanessa Porkolab, PhD, explores why binding-first strategies are gaining momentum in drug discovery, enabling deeper insights into target engagement, mechanism of action, and next-generation modalities. Don’t miss the next issue, subscribe here: https://lnkd.in/eqWg2aD6 #Eurofins #EurofinsDiscovery #DrugDiscovery #Biophysics #Kinases #PROTACs #MolecularGlues

Late-stage safety findings can derail promising drug candidates. Download De-Risking Drug Candidates Through Modernized In Vitro Safety Pharmacology to learn how today's approaches to secondary pharmacology can help identify risks earlier and improve decision-making across discovery programs. Inside: ✔️ Strategies for aligning safety screening with project goals ✔️ A clear overview of the latest 2024 recommendations for expanded target coverage ✔️ How AI-driven visualization tools can turn complex data into actionable insights Download the guide: https://lnkd.in/dBS9jhZK #DrugDiscovery #SafetyPharmacology #SAFETYscan #SafetyScreen #EurofinsDiscovery

Eurofins Discovery anticipates challenges and addresses them with comprehensive de-risking strategies. Our program management team handles admin tasks, while our scientific leaders work with you to anticipate the challenges and address them with comprehensive de-risking strategies. We can rapidly enable project initiation with our 12,000+ ready-to-use assays and gain early toxicity insights with our proprietary BioMAP® technology, a comprehensive menu of human primary cell disease models for testing candidates across 100s of clinically relevant protein biomarkers. Key areas: • Flexible models including proof-of-concept packages, integrated programs, fee-for-service, and FTE support. • Modality-agnostic approach spans both small molecules and Biotherapeutics, ensuring comprehensive support for diverse discovery programs. • Deep expertise in all phases of discovery and in delivering complete drug candidate screening programs with over 40 INDs & 5 commercially approved drugs from concept to clinical testing. This empowers you with the capabilities of a global pharma leader while maintaining the agility and speed essential for innovation – reach out now to learn more! https://lnkd.in/epPmDFY9 #Eurofins #EurofinsDiscovery #DrugDiscovery #IDD

Eurofins Discovery offers Pharma, Biotech and AI-driven drug discovery teams one of the industry’s most comprehensive suite of validated GPCR assays – over 2,750 robust, automation-compatible formats – designed to streamline every phase of drug discovery. Whether you're deorphanizing receptors, validating AI-predicted hits, or screening 500K+ compounds, our integrated workflows and diverse libraries deliver actionable insights. Key benefits: • Comprehensive profiling of ligand binding, signaling, and mechanism of action • Data-rich outputs compatible with machine learning workflows • Diverse GPCR-focused, small molecule and virtual screening libraries • End-to-end support from hit identification to lead optimization • Access to the @Eurofins DiscoverX® portfolio of sensitive, scalable, and robust GPCR products Well-respected for our scientific leadership, Eurofins Discovery becomes an extension of your team and a strategic partner in advancing GPCR-targeted therapeutics. Learn more and reach out: https://lnkd.in/eH-7SSK9 #Eurofins #EurofinsDiscovery #DrugDiscovery #GPCR

Eurofins Discovery is a trusted partner in kinase research, offering broad coverage across more than 500 kinases for Pharma, Biotech and AI-driven drug discovery researchers. Our solutions combine seamless compound management, fast turnaround times, and high-confidence selectivity profiling across both standard and customized panels. Generate actionable insights with binding affinity and functional activity data using our industry-leading kinase inhibitor discovery platforms, KINOMEscan® and KinaseProfiler™. Platform highlights: • Compatible from early discovery to hit finding to lead optimization to candidate selection • Optimal for investigating allosteric, covalent, noncovalent, or bifunctional inhibitors and degraders • Amenable to screening small molecules, peptides, conjugate and multi-functional therapeutic • Short turn-around time to meet aggressive project timelines for rank-ordering and SAR With access to unique wild-type and mutant human kinases, you can make confident decisions about therapeutic opportunities and off-target risks, while benefitting from instant access to Eurofins DiscoverX® high-quality proteins. Explore our kinase panels and select the right fit for your program: https://lnkd.in/e28DAxRA #Eurofins #EurofinsDiscovery #DrugDiscovery #KinaseResearch